Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | TK1 | P04183 | 1/20 | 0.49 |
| ▸ | TK2 | O00142 | 9/20 | 0.48 |
| ▸ | TYMP | P19971 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16207975 | 0.84 | DRD2 (0.48) | ADRA1DADRA1AADRA1BDRD2DRD3 | |
| SCHEMBL593713 | 0.80 | HPGD (0.65) | ADRA1DADRA1AADRA1BTK1TK2 | |
| SCHEMBL2349488 | 0.80 | ADRA1D (0.58) | ADRA1DADRA1AADRA1BDRD2DRD3 | |
| SCHEMBL591628 | 0.79 | MAPK1 (0.58) | ADRA1DADRA1AADRA1BDRD2DRD3 | |
| SCHEMBL2353857 | 0.79 | ADRA1B (0.68) | ADRA1DADRA1AADRA1BDRD2DRD3 | |
| SCHEMBL2349762 | 0.79 | ADRA1D (0.56) | ADRA1DADRA1AADRA1BDRD2DRD3 | |
| SCHEMBL591722 | 0.79 | HPGD (0.52) | ADRA1DADRA1AADRA1BDRD2DRD3 | |
| SCHEMBL2352931 | 0.78 | DRD2 (0.56) | ADRA1DADRA1AADRA1BDRD2DRD3 | |
| SCHEMBL592961 | 0.78 | DRD2 (0.51) | ADRA1DADRA1AADRA1BDRD2DRD3 | |
| SCHEMBL2354965 | 0.77 | ADRA1A (0.66) | ADRA1DADRA1AADRA1BDRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828146-B1 | SUBSTITUTED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | ABBVIE DEUTSCHLAND (DE) | 2014-11-05 | — | — | EP | claimed |
| EP-1828146-B1 | SUBSTITUTED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | ABBVIE DEUTSCHLAND (DE) | 2014-11-05 | — | — | EP | disclosed |
| US-8114875-B2 | Substituted N-heterocyclic compounds and their use as dopamine D3 receptor ligands | ABBOTT GMBH & CO. KG (DE) | 2012-02-14 | — | — | US | disclosed |
| US-20090054449-A1 | Substituted N-heterocyclic Compounds and Their Use as Dopamine D3 Receptor Ligands | ABBOTT GMBH & CO. KG (DE) | 2009-02-26 | — | — | US | disclosed |
| EP-1828146-A1 | SUBSTITUTED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | Abbott GmbH & Co. KG (DE) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006066885-A1 | SUBSTITUTED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054449-A1 | Substituted N-heterocyclic Compounds and Their Use as Dopamine D3 Receptor Ligands | SLC6A3, DRD3, HTR3A | ADRA1D 52/4885ADRA1A 86/4885ADRA1B 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.